Oxford Biomedica (OXB) Share Price, News & Analysis

Company Overview

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Key Stats

• Today's Range: 400.50 to 416.28
• 50-Day Range: 334.50 to 445
• 52-Week Range: 164.29 to 450
• Volume: 1.24 million shs
• Average Volume: 209,957 shs
• Market Capitalization: £434.61 million
• P/E Ratio: N/A
• Dividend Yield: 4.57%
• Price Target: GBX 433.33
• Consensus Rating: Hold

Oxford Biomedica Stock Analysis - MarketRank™

Oxford Biomedica scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Oxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oxford Biomedica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oxford Biomedica is -286.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oxford Biomedica is -286.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oxford Biomedica has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OXB.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Oxford Biomedica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OXB.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Oxford Biomedica has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Oxford Biomedica this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oxford Biomedica insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.17% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.13% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OXB Stock Analysis - Frequently Asked Questions

How have OXB shares performed this year?

Oxford Biomedica's stock was trading at GBX 220 at the start of the year. Since then, OXB shares have increased by 87.7% and is now trading at GBX 412.95.
View the best growth stocks for 2024 here.

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Barclays (BARC).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OXB
• CUSIP: N/A
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: +44-1865-783000
• Fax: N/A
• Employees: 891
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 433.33
• High Stock Price Target: GBX 740
• Low Stock Price Target: GBX 180
• Potential Upside/Downside: +4.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-142,020,000.00
• Net Margins: -145.98%
• Pretax Margin: N/A
• Return on Equity: -124.66%
• Return on Assets: -12.67%

Debt

• Debt-to-Equity Ratio: 154.88
• Current Ratio: 2.35
• Quick Ratio: 1.67

Sales & Book Value

• Annual Sales: £97.28 million
• Price / Sales: 4.47
• Cash Flow: GBX 137.37 per share
• Price / Cash Flow: 3.01
• Book Value: GBX 63 per share
• Price / Book: 6.56

Miscellaneous

• Outstanding Shares: 105,360,000
• Free Float: N/A
• Market Cap: £435.14 million
• Optionable: Not Optionable
• Beta: 1.09